Medicines Used in De-Addiction Treatment: A Complete Guide | Mindtalk

De-addiction treatment is most effective when it addresses all three dimensions of addiction: biological, psychological, and social. Medication handles the biological component — reducing the intensity of withdrawal, blocking the pleasurable effects of substances, or creating deterrents to use — while therapy and counselling address the psychological patterns and the social support needed for sustained recovery. Medication alone is not sufficient for lasting recovery, but it significantly improves the odds when combined with a structured treatment programme.

Important: All medications mentioned in this article should only be taken under the supervision of a qualified psychiatrist or addiction medicine specialist. Do not self-medicate. If you or a family member needs support with de-addiction, Mindtalk's addiction psychiatrists can assess the appropriate approach and begin treatment.

Why Are Medicines Used in De-Addiction?

Addiction involves measurable changes to brain chemistry — particularly to the dopamine reward system and the systems regulating stress, decision-making, and impulse control. These changes do not reverse immediately when substance use stops. In the absence of the substance, the altered brain chemistry produces withdrawal symptoms and intense cravings that make relapse extremely likely without support.

Medication-assisted treatment (MAT) works by targeting this altered brain chemistry directly. Depending on the medication, it may reduce physical cravings, block the pleasurable effects that reinforce continued use, ease post-acute withdrawal discomfort, or create an aversive reaction to substance use that acts as a deterrent. Studies consistently show that MAT approximately doubles recovery rates compared to psychosocial treatment alone for alcohol and opioid dependence. The WHO classifies several of these medicines — including naltrexone and buprenorphine — as essential medicines based on their evidence base and safety profile.

Medicines for Alcohol De-Addiction

Three main medications are used in the management of alcohol use disorder after the acute detox phase. The appropriate choice depends on the individual patient's profile, medical history, and treatment goals.

Disulfiram (Antabuse) works by blocking the enzyme that metabolises acetaldehyde (a byproduct of alcohol metabolism). When a person taking disulfiram consumes alcohol, acetaldehyde accumulates rapidly, causing an extremely unpleasant reaction: nausea, flushing, palpitations, and general physical distress. This aversive reaction acts as a strong deterrent. Disulfiram is most effective when the patient is highly motivated and has external accountability — family supervision of the dose improves adherence significantly. It is the oldest medication used in alcohol de-addiction, with a well-established track record.

Naltrexone works differently — it is an opioid receptor antagonist that blocks the brain's reward pathway. Alcohol partly produces its pleasant effects by stimulating opioid receptors; naltrexone blocks these receptors, reducing the pleasurable effects of alcohol and suppressing the craving for another drink once the first has been taken. It is available as a daily oral tablet or as a monthly injection (extended-release naltrexone). It is particularly useful for patients who struggle with the "one drink triggers a binge" pattern.

Acamprosate targets the GABA and glutamate neurotransmitter imbalance that chronic alcohol use creates. After detox, this imbalance produces persistent discomfort — anxiety, restlessness, and a generalised sense of dysphoria — that drives relapse even after the acute withdrawal phase has passed. Acamprosate reduces this post-acute withdrawal discomfort, making abstinence easier to sustain in the months after detox. It works best in patients who have completed a medical detox and are committed to full abstinence.

Medicines for Opioid De-Addiction

Opioid use disorder (involving heroin, prescription opioids, or other opioid substances) responds well to medication-assisted treatment. The following medications are used across two phases: acute withdrawal management and long-term recovery maintenance.

Buprenorphine (and Buprenorphine-Naloxone / Suboxone) is the most widely used opioid substitution therapy in India and globally. Buprenorphine is a partial opioid agonist — it activates opioid receptors enough to prevent withdrawal and reduce cravings without producing the intense euphoria associated with full agonists like heroin. The ceiling effect on its euphoric potential makes it significantly safer. The combination product (buprenorphine plus naloxone) is designed to discourage injection misuse — if injected, the naloxone component precipitates immediate withdrawal. Buprenorphine is dispensed under a psychiatrist's prescription and is the cornerstone of most opioid de-addiction programmes in India. It is worth clarifying that opioid substitution therapy is not "substituting one addiction for another" — it is evidence-based medical treatment endorsed by the WHO that reduces illegal drug use, overdose deaths, and HIV transmission.

Methadone is a long-acting full opioid agonist that reduces cravings and blocks the euphoric effects of other opioids when taken at the right therapeutic dose. It is highly effective for severe opioid dependence and has decades of evidence behind it. In India, methadone is dispensed only through licensed centres because its management requires careful dose titration and supervision. It is typically reserved for patients who have not responded to buprenorphine.

Naltrexone (post-detox) is also used in opioid de-addiction after a patient has completed full medical detox and is opioid-free. At that point, naltrexone blocks opioid receptors completely, meaning that if the patient relapses and uses an opioid, they will experience no euphoric effect. This "blocking" approach is effective for highly motivated patients with strong social support, though it requires complete abstinence from opioids before starting (starting naltrexone too early precipitates immediate severe withdrawal).

Clonidine is used during the acute withdrawal management phase to reduce the severity of autonomic withdrawal symptoms — sweating, anxiety, rapid heart rate, and agitation. It is not a maintenance medication and does not reduce cravings, but it makes the detox phase more tolerable and reduces the risk of patients leaving treatment prematurely.

Medicines for Co-occurring Mental Health Conditions

A significant proportion of people seeking de-addiction treatment have co-occurring mental health conditions — depression, anxiety disorders, PTSD, or ADHD — a presentation known as dual diagnosis. Treating only the addiction without addressing the underlying mental health condition significantly increases relapse risk, because the mental health condition often drives substance use as a coping mechanism.

In these cases, the addiction psychiatrist may prescribe antidepressants, mood stabilisers, or ADHD medications alongside de-addiction medicines. Getting this combination right requires careful assessment, as some antidepressants can interact with de-addiction medications. A psychiatrist experienced in dual diagnosis treatment will manage this as an integrated programme. For more on this topic, see Mindtalk's overview of drug addiction and the de-addiction treatment programme.

Medication Is Only Part of the Picture

De-addiction medicines manage the biological dimensions of addiction — they reduce cravings, ease withdrawal, and create deterrents or blockers that make it easier to choose not to use. But sustained recovery requires more than biology. Psychological recovery — understanding the triggers that drove use, building new coping strategies, repairing relationships, and constructing a life in which substance use is no longer the primary source of relief — requires therapy.

The most effective de-addiction programmes combine medication with Cognitive Behavioural Therapy (CBT), motivational interviewing, group therapy, family support, and aftercare planning. The medication creates the biological stability that makes engaging with therapy possible; therapy does the work of building the psychological and social foundations that prevent relapse.

Mindtalk's addiction psychiatrists design integrated de-addiction programmes that combine evidence-based medication management with the therapeutic work needed for lasting recovery. Speak to our specialists to understand the right approach for your situation.